List view / Grid view
24 July 2014 | By Biogen Idec
Biogen Idec announced that the European Commission has granted marketing authorization for PLEGRIDYTM (peginterferon beta-1a)...
24 July 2014 | By Merck
Merck announced that the first patient has been enrolled in a global Phase 3 clinical study of letermovir (MK-8228)...
24 July 2014 | By Eli Lilly and Company & Daiichi Sankyo
Revised guidance from the National Institute for Health and Care Excellence, recommends once-daily, oral antiplatelet prasugrel (Efient®)...
23 July 2014 | By Sucampo Pharmaceuticals, Inc
Sucampo Pharmaceuticals, Inc. announced that the United Kingdom’s National Institute of Health and Care Excellence has published the technology appraisal guidance recommending the use of AMITIZA® (lubiprostone)...
22 July 2014 | By AstraZeneca
AstraZeneca announced that MedImmune has entered into a clinical trial collaboration with Advaxis, Inc., a US-based biotechnology company developing cancer immunotherapies...
22 July 2014 | By GlaxoSmithKline
...with emtricitabine/tenofovir plus darunavir/ritonavir in treatment-naïve adults with HIV-1.
22 July 2014 | By Boehringer Ingelheim
...to investigate new therapeutic concepts in the field of ubiquitin signalling biology.
GE has announced the release of its new Sievers M9 Total Organic Carbon (TOC) Analyzer, which has been designed to measure TOC in a broad range of samples from ultrapure water to process waters. The new M9 Analyzer enhances productivity by producing TOC results in two minutes, twice as fast…
21 July 2014 | By Teva
...opens door to a strong and novel migraine prevention and treatment franchise within its CNS portfolio.
Thermo Fisher Scientific, the world leader in serving science, today unveiled a new high performance liquid chromatography system designed from the ground up to provide new levels of performance, productivity and usability when used as a standalone system or with the latest mass spectrometers
18 July 2014 | By AstraZeneca
AstraZeneca revealed the proposed designs for its new Global R&D Centre and Corporate Headquarters in Cambridge in the UK...
18 July 2014 | By Amgen
Amgen announced that a Phase 3 study evaluating AMG 416 (formerly known as velcalcetide) for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease...
18 July 2014 | By GlaxoSmithKline
...phase III BRAF V600-mutant metastatic melanoma study stopped early.
18 July 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company and Pfizer Inc. announced that the first patient has been enrolled into a Phase IV clinical trial called EMANATE assessing the effectiveness and safety of Eliquis in patients with nonvalvular atrial fibrillation undergoing cardioversion...
17 July 2014 | By Roche
Roche presented data from two phase II studies investigating whether crenezumab can delay cognitive and functional decline in people with mild-to-moderate Alzheimer’s disease...
